Fundraising FoxBiosergen
1 known investors
Find your way into Biosergen
Sign up to see every warm intro you have to Biosergen
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Biosergen team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Biosergen is a biotech company developing antifungal drugs to treat life-threatening invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients. Its lead drug candidate, BSG005, is a polyene macrolide invented at the Norwegian University of Science and Technology with SINTEF, and the company is listed on Nasdaq First North Growth Market in Stockholm.
Investors · 1
Frequently asked questions
- What does Biosergen do?
- Biosergen is a biotech company developing antifungal drugs to treat life-threatening invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients. Its lead drug candidate, BSG005, is a polyene macrolide invented at the Norwegian University of Science and Technology with SINTEF, and the company is listed on Nasdaq First North Growth Market in Stockholm.
- Who are Biosergen's investors?
- Biosergen's investors include Rosetta Capital Ltd..